Effective Long-term Prophylaxis with BAY 94-9027 in Previously Treated Children: Interim Results of the PROTECT VIII Kids Extension Study
Objective: BAY 94-9027 is an extended–half-life recombinant factor VIII (FVIII) product. In the PROTECT VIII Kids trial, BAY 94-9027 was efficacious for the prevention and treatment of bleeding episodes in previously treated…
PROTECT VIII Extension Trial Interim Data: Safety of >5 Years of Treatment With BAY 94-9027
Objective: BAY 94-9027 is an extended–half-life recombinant factor VIII (FVIII) product. In the PROTECT VIII study, BAY 94-9027 provided effective protection against bleeds and was well tolerated with twice-weekly, every-5-day,…
Effects of Factor VIII Prophylaxis on Vascular Remodeling and Synovial Gene Expression Changes Associated with Hemarthrosis in FVIII-Deficient Mice
Objective: Repeated joint bleeding in patients with hemophilia leads to hemophilic arthropathy (HA), which cannot be entirely prevented by clotting factor replacement. Vascular remodeling and permeability are associated with…
An update on cognitive and behavior function in children and young adults with hemophilia: a 25-year journey from the Hemophilia Growth and Development Study to the current eTHINK study
Objective: The Evolving Treatment of Hemophilia’s Impact on Neurodevelopment, Intelligence and Other Cognitive Functions (eTHINK) study aims to evaluate the impact of hemophilia on neurodevelopment and cognitive function through…
Improving the screening for and evaluation of bleeding disorders in the primary care setting
Efficacy of on-demand treatment of bleeding episodes in hemophilia B patients with extended half-life N9-GP in pivotal trials: an in-depth analysis of treatment
Objective: N9-GP is a glycoPEGylated recombinant factor-IX (rFIX) product that provides approximately two times incremental recovery, five times half-life, and 10 times area under the plasma concentration-time curve compared with…
Real-world bleeding outcomes and adherence metrics among persons with hemophilia A and B receiving standard or extended half-life factor replacement products
Objective: We sought to explore real-world outcomes, such as annualized bleeding rate (ABR) and markers of adherence, in persons with hemophilia A (PwHA) or with hemophilia B (PwHB) who receive standard half-life (SHL) or…
Gender Differences in Parenting Stress and Social Support in Hemophilia Families
Camp Warren Jyrch
Camp Warren Jyrch allows Illinois kids with bleeding disorders a chance to come together, empower each other, and learn more about their disorders, how to self-treat, and gain independence, all while experiencing everything that children without…
Camp High Hopes
We're more than a camp, we're a family. Come see for yourself! Camp High Hopes Inc. has offered a Summer Camp Program for 7 to 17 year old boys with bleeding disorders since 1986. The majority of our Board of Directors and Counselors were campers at…